Profile: CEL-SCI Corp (CVM)
27 Sep 2016
CEL-SCI Corporation, incorporated on March 22, 1983, is a biotechnology company. The Company is engaged in the research and development of drugs and vaccines. The Company researches and develops immunotherapy products for the treatment of cancer and infectious diseases. The Company's product pipeline consists of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy against cancer and Human Papilloma Virus (HPV), and Ligand Epitope Antigen Presentation System (LEAPS) technology, with two investigational therapies, LEAPS-H1N1-DC pandemic flu treatment for hospitalized patients, and CEL-2000, a rheumatoid arthritis treatment vaccine.
The Company's lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in the Phase III clinical trial against head and neck cancer. The Company has received Orphan Drug Status from the United States Food and Drug Administration for Multikine.
The Company's patented T-cell Modulation Process, referred to as LEAPS uses heteroconjugates to direct the body to choose a specific immune response. LEAPS is the Company's pre-clinical technology. LEAPS is designed to stimulate the human immune system to treat bacterial, viral and parasitic infections, as well as autoimmune, allergies, transplantation rejection and cancer. Using the LEAPS technology, the Company has created a peptide treatment for H1N1 (swine flu) hospitalized patients.
8229 Boone Blvd Ste 802
VIENNA VA 22182-2634
Company Web Links
- BRIEF-CEL-SCI says arbitration hearing scheduled to begin on Sept 26 - sec filing
- BRIEF-CEL-SCI announces $5 mln registered direct offering
- BRIEF-Cel-Sci Q3 loss per share $0.03
- BRIEF-Cel-Sci enters agreement with healthcare institutional investor to purchase about 10 mln shares of common stock and warrants
- BRIEF-Cel-Sci Corporation Q2 loss per share $0.07